CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...